Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Invested Capital (2020 - 2025)

Historic Invested Capital for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to -$8.1 million.

  • Insight Molecular Diagnostics' Invested Capital fell 17883.78% to -$8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.1 million, marking a year-over-year decrease of 17883.78%. This contributed to the annual value of -$12.0 million for FY2024, which is 15287.51% down from last year.
  • According to the latest figures from Q3 2025, Insight Molecular Diagnostics' Invested Capital is -$8.1 million, which was down 17883.78% from $1.8 million recorded in Q2 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Invested Capital peaked at $114.4 million during Q2 2021, and registered a low of -$12.0 million during Q4 2024.
  • In the last 5 years, Insight Molecular Diagnostics' Invested Capital had a median value of $34.4 million in 2022 and averaged $41.3 million.
  • In the last 5 years, Insight Molecular Diagnostics' Invested Capital surged by 18647.34% in 2021 and then crashed by 17883.78% in 2025.
  • Insight Molecular Diagnostics' Invested Capital (Quarter) stood at $66.6 million in 2021, then crashed by 48.35% to $34.4 million in 2022, then plummeted by 33.78% to $22.8 million in 2023, then tumbled by 152.88% to -$12.0 million in 2024, then surged by 32.43% to -$8.1 million in 2025.
  • Its last three reported values are -$8.1 million in Q3 2025, $1.8 million for Q2 2025, and $10.7 million during Q1 2025.